From The Life Sciences Report: Regenerative Medicine in Japan: CJ PARTNERS' Colin Lee Novick
Wednesday, 5 August 2015
Regenerative medicine is just beginning to be understood by governments and investors alike. Last autumn, new regulations took effect in Japan that promise to speed patient access to some of these new therapies. In an interview with The Life Sciences Report, Colin Lee Novick, managing partner with CJ PARTNERS, describes Japan's regenerative medicine frontier and lists investment-worthy companies that are pushing the boundaries.
RGS Price at posting:
13.5¢ Sentiment: None Disclosure: Held
